Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years.

Riobaldo M CintraAna Claudia NogueiraIsabella BonilhaBeatriz M LuchiariOtavio R Coelho-FilhoOtavio R CoelhoPedro SchwartzmannElza MuscellieWilson NadruzLuiz Sergio F CarvalhoAndrei Carvalho Sposito

Published in: The Journal of clinical endocrinology and metabolism (2021)

The risk of HHF is reduced by SGLT2is as monotherapy or in combination with DPP4is and increased by TZDs as monotherapy or in combination. Glucose-lowering provides an additive effect of reducing HHF.

Keyphrases

heart failure
systematic review
combination therapy
blood glucose
open label
meta analyses
case report
left ventricular
randomized controlled trial
atrial fibrillation
clinical trial
cardiac resynchronization therapy
insulin resistance
metabolic syndrome
skeletal muscle
adipose tissue
study protocol